Breaking News

Merck, PAREXEL Form Strategic Biosimilar Alliance

Merck and PAREXEL International Corp. have entered into an alliance under which PAREXEL will provide access to global clinical development services for designated biosimilar candidates to Merck BioVentures, a division of Merck.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck and PAREXEL International Corp. have entered into an alliance under which PAREXEL will provide access to global clinical development services for designated biosimilar candidates to Merck BioVentures, a division of Merck. PAREXEL will provide access to regulatory strategy and clinical development planning capabilities for the development of various classes of biosimilars across multiple therapeutic areas, including exclusivity for certain candidates. The agreement also provides for the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters